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Fanconi Anemia (FA) is a rare autosomic re-
cessive  and  X-linked  disease  with  chromo-
somal  instability  after  exposure  to  cross-
linking agents as the hallmark. Clinical fea-
tures  of  FA  are  somatic  malformations,  pro-
gressive  bone  marrow  failure  and  cancer
proneness, however there is wide clinical het-
erogeneity. The symptom most frequently and
early associated with morbidity and mortality
is progressive pancytopenia in the first decade
of life although acute myelogenous leukemia
(AML)  or  myelodysplastic  syndrome  (MDS)
can appear before aplastic anemia. Squamous
cell carcinoma (SCC) of the head-neck, intes-
tinal or genital tract has a very high incidence
in FA and can appear at young age. This paper
will focus on treatment of bone marrow failure
in FA.
Introduction
Fanconi Anemia (FA) is a rare autosomic re-
cessive and X-linked disease with wide clinical
and  biological  heterogeneity.  The  gold  stan-
dard  diagnostic  criteria  of  FA  is  increased
chromosome fragility after exposure to alchy-
lating agents such as diepoxybutane (DEB) or
mitomycine C (MMC). The most frequent clin-
ical  features  are  progressive  bone  marrow
failure, somatic abnormalities and cancer sus-
ceptibility.  Altered  skin  pigmentation  and/or
café  au  lait  spots,  short  stature,  thumb  or
thumb and radial anomalies, abnormal male
gonads,  microcephaly,  eye  anomalies,  struc-
tural renal defects, low birth weight, develop-
mental delay, and abnormal ears or hearing are
the most frequent birth defects. However about
25-40% of FA patients have a normal or nearly
normal somatic phenotype.1 The reported inci-
dence  of  FA,  probably  underestimated,  is  3
cases/million newborn/year and the disease is
slightly more frequent in males than females,
the ratio being 1.3/1. The carrier frequency is
1/300  in  USA  and  western  Europe,  whereas
among  some  populations  such  as  South
African  Afrikaaners,  Ashkenazi  Jews  and
Spanish Gypsies the frequency is higher, about
1/90-1/100,  due  to  genetic  founder  effects.1-3
To  date  there  are  14  FA  complementation
groups  corresponding  to  14  different  cloned
genes: FANCA, B, C, D1, D2, E, F, G, I, J, L, M, N
and P. More than 2/3 of Fanconi patients belong
to  FA-A,  FA-C  or  FA-G  group  with  FA-A  ac-
counting for more than 50%. Although most are
unique genes, several were previously known,
including FANCD1 (BRCA2), FANCG (XRCC9),
FANCI (KIAA1794),  FANCJ (BRPI1/BACH1),
FANCL (PHF9/POG),  FANCM (Hef),  FANCN
(PALB2) and FANCP (SLX4). Heterozygotes for
BRCA2 and possibly BACH1 and PALB2 are at
increased risk of breast cancer and other can-
cers. In addition there are 3 other genes in-
volved in the pathway but not yet found in any
patient and therefore not formally designated
as  FA  genes:  RAD51C,  DDX11,  FAAP20. The
Fanconi anemia proteins A, B, C, E, F, G, L and
M  appear  to  form  a  nuclear  complex,  which
leads to ubiquitination of the I and D2 proteins;
the latter is involved in DNA damage response
mechanisms  in  cooperation  with  FANCD1,
FANCJ, FANCN and FANCP, as well as BRCA1,
RAD51, Mre11, and other proteins.
The  widely  variant  FA  phenotype  may  de-
pend on whether the mutation in the involved
FA gene is null or leads to a partially functional
gene product rather than the specific gene that
is involved. Attempts to do genotype-phenotype
correlations in FA have shown contrasting re-
sults between different studies and high-light
the genetic and clinical heterogeneity in the
population. In addition, somatic reversion of
the germ-line mutation in a FA gene leading to
mosaicism, defined by the presence of two ge-
netically different cell populations in the or-
ganism, one normal and one Fanconi, further-
more increases the difficulty in genotype- phe-
notype correlations. Hence, the specific role of
the Fanconi Anemia proteins in the pathogen-
esis  of  somatic  abnormalities,  bone  marrow
failure, or oncogenesis remain to be clarified.
Other than birth defects the most frequent
presentation of FA leading to diagnosis is pro-
gressive  bone  marrow  failure  appearing
during the first decade of life. Early signs be-
fore peripheral blood cytopenia becomes evi-
dent  may  be  progressively  increasing  mean
corpuscular  volume  (MCV)  and  HbF.  Actual
aplastic anemia may be preceded by myelos-
dysplastic syndrome (MDS) or acute myeloge-
nous leukemia (AML) and chromosomal aber-
rations involving chromosome 3 and 7 lead to
increased  risk  of  developing  MDS/AML.4 As
cancer can be the only manifestation of FA, it
should  be  suspected  in  cases  of  early  onset
head-neck  squamous  cell  carcinoma  (SCC),
esophageal or vulvar cancer. This paper will
focus on management and treatment of bone
marrow failure in FA.
Marrow failure in FA prompts a comprehen-
sive monitoring plan consisting of clinical ex-
amination  and  at  least  yearly  bone  marrow
studies,  including  morphology,  cytogenetics,
FISH, colony studies and immunophenotyping.
At  diagnosis  parents  and  siblings  should  be
evaluated by DEB test and by molecular genetic
testing if the patient has a known mutation. At
diagnosis, even if the marrow failure is at a
very early stage, the patient and family should
be HLA typed, because 1st choice treatment is
hematopoietic  stem  cell  transplantation
(HSCT)  if  an  HLA  matched  family  donor  is
available. If no family donor is available an un-
related  donor  search  should  be  initiated  as
soon as possible. The reason for the urgency to
identify a donor is because the earlier trans-
plant is done, to a younger patient who has not
received  transfusions,  the  better  is  the  out-
come.
Due to the chromosome fragility inherent to
the FA cells, FA patients display extraordinary
toxicity  when  treated  with  chemo-  or  radio-
therapy. Therefore the conditioning regimen
prior to HSCT must be reduced compared to
other patient groups. Using irradiation in the
preparative regimen has been debated over the
past decades. Several groups have reported re-
sults after transplant with or without total body
irradiation (TBI), the results are summarized
in Table 1. A registry analysis that compared ir-
radiation vs non irradiation in 148 FA patients
registered  to  the  Center  for  International
Blood  and  Marrow  Transplant  Research
(CIBMTR) database receiving an HLA-matched
sibling  transplant  between  1991  and  2001
showed no differences in engraftment, acute
and chronic GVHD, transplant related mortality
(TRM) or OS in the two groups.5 The message
was therefore in support to the use of non-irra-
diation  preparative  regimen.  The  follow-up
was too short to evaluate if irradiation was as-
sociated with increased risk of tumours.
Regarding timing of HSCT from a matched
family donor, published experience leads us to
suggest that transplant should be performed in
early marrow failure, as manifested by mild cy-
topenia and hypoplasia of marrow hematopoi-
etic tissue but before cytopenia becomes se-
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40x109/L, before transfusion requirement, and
before appearance of cytogenetic aberrations
involving chromosome 3 and 7 and/or AML. Age
at transplant is consistently a prognostic factor
with  better  outcome  if  performed  before  10
years. The evidence suggest that conditioning
regimen for a matched family donor transplant
should be without irradiation, using fludara-
bine and cyclophosphamide and with T cell de-
pletion (TCD), either of the graft or in vivo
with  Mabcampath  for  example,  to  prevent
GVHD.
In case a matched family donor is not avail-
able, a donor search in international registries
should  be  started  as  soon  as  possible  and
transplant  should  be  performed  essentially
with  the  same  criteria  as  a  matched  family
donor transplant, i.e. before severe cytopenia
requiring transfusions and before appearance
of a cytogenetic clone and/or AML. Regarding
the conditioning regimen in alternative donor
transplants, there is no doubt that fludarabine
has changed the outcome relevantly, from pre-
viously very poor, improving survival and en-
graftment  and  reducing  early  mortality  and
transplant related mortality (TRM).6 The use
of  irradiation  varies  between  countries  and
transplant centres, as summarized in Table 2.
In three consecutive phase II clinical trials as-
sessing  the  optimal  approach  to  alternative
donor transplants, MacMillan et al. confirmed
in multivariate analysis that age >10 years and
any transfusion prior to transplant was associ-
ated with higher 3-year mortality. Among these
trials, a TBI dose de-escalation from 300 to 150
cGy led to secondary graft failure in 2/2 pts and
therefore dose de-escalation was stopped and
returned to 300 cGy.7 A single-center report of
7 patients transplanted with alternative donors
without irradiation resulted in 22% rejection
rate which however could be recuperated with
a second transplant and all patients were alive
at median 3 years follow-up.8 Bonfim et al. re-
ported 60 patients receiving alternative donor
transplants without irradiation obtaining OS
at 5 years 92% for patients below 10 years of
age and 53% for patients above 10 years. Note-
worthy  in  this  report,  10  patients  developed
tongue carcinoma, 7 of whom had had GVHD.9
(C. Bonfim, update of ref 9 as oral communica-
tion, FARF Scientific Symposium 2010) This
highlights the importance of reducing GVHD,
by TCD of the graft or in vivo TCD using Mab-
campath and/or ATG.
Unrelated Cord blood (UCB) as an alterna-
tive stem cell source to bone marrow or periph-
eral  blood  has  been  reported  in  a  registry
based analysis of 93 UCB in FA where OS was
53% with Fludarabin in the conditioning reg-
imen (vs 19% non Fludarabin). There were rel-
atively high figures of GVHD and TRM, 32%
and 59% respectively.10 As of today, UCB trans-
plant should be considered only when other al-
ternative  donor  stem  cell  source  cannot  be
found. Preliminary results from a retrospective
analysis of the EBMT database show that mis-
matched or haploidentical family donors may
be a valid option if no matched unrelated donor
can be found (E. Korthof, oral communication
FARF  Scientific  Symposium  2010).  In  sum-
mary,  alternative  donor  transplants  are  im-
proving  in  survival,  getting  close  to  that  of
matched  sibling  donor  transplants,  whereas
TRM and GVHD are still a problem. It is still an
unresolved issue whether to perform irradia-
tion or not. Furthermore, the intrinsic cancer
proneness in FA significantly increases with
acute severe and chronic GVHD and in general
a 4.4-fold higher risk for SCC was found in pa-
tients who received transplants vs who did not.
The cumulative incidence of SCC was 24% at
15 years after transplant and SCC manifested
at  younger  age  in  transplanted  FA  patients
compared to non transplanted.11
Other  treatment  alternatives  for  marrow
failure  in  FA  are  only  temporary  options
awaiting  HSCT  which  is  the  only  treatment
that can cure bone marrow failure and prevent
the risk of hematologic malignancy. The use of
androgens,  oxymetholone  at  the  dose  of  2-5
mg/kg/day,  can  bridge  the  gap  to  HSCT,  but
should be avoided long-term due to side-effects
including masculinization, final short stature,
peliosis hepatis, liver adenomas and hepato-
cellular carcinomas. Androgens were reported
to adversely affect the outcome of subsequent
HSCT in some studies12 but not in others.13
Hematopoietic growth factors such as EPO and
G-CSF have no demonstrated effect. G-CSF has
the potential risk of stimulating clonal escape
and should be used only in rare cases of severe
infections  in  neutropenia.  Anti-fungal  agent
voriconazole should be used with caution due
to increased risk of SCC14 (AIFA nota informa-
tiva 22/9/10). Experimental trials studying the
safety  and  efficacy  ofanti-TNF  alpha  agent
etanercept in FA, based on the in vitro benefi-
cial effect of etanercept on colony formation in
FA marrow mononuclear cells15 are currently
being evaluated.
There is limited experience on treatment of
Article
Table 1. Matched family donor transplant: conditioning regimen and outcome.
Dufour et al. Farzin et al. Tan et al. Ayas et al. Bonfim et al.
(BJH 2001)18 (BJH 2007)19 (PBC 2006)20 (BMT 2008)21 (BBMT 2007)9
Patient nr 27 35 11 34 67
Conditioning TAI/TBI 500cGy, TAI/TBI 400cGy, LD CY + FLU CY 60 mg/kg,  CY 60 mg/kg
LDCY or HDCY LDCY, ATG 125 mg/m2, ATG, TCD ATG
Graft failure 8% 5,7% 9% 0 10,5%
Ac GVHD 36% 14,2% 0 17%
Cr GVHD 12,5% 12% 0 28%
TRM 18,5% 8,5% 9% 9%
Late tumours 0 5,7% 3%
Follow-up 3 yrs 10 yrs 2 yrs 2,9 yrs 3,7 yrs
OS 81,5% 83% 100% 97% 97%
EFS 82% 82%
LDCY: low dose cyclophosphamide, 20 mg/kg; HD CY: high dose cyclophosphamide, 100-200 mg/kg; TCD: T Cell depleted graft; ATG: anti lymphocyte
globuline.
Table 2. Matched unrelated donor transplants: conditioning regimen and outcome.
MacMillan Chaudhury Yabe Bonfim Motwani
et al. et al. et al. et al. et al.
(BBMT 2009)9 (BJH 2008)22 (BJH 2006)23 (oral commu- (BMT 2005)8
nication 2010)9
Patient nr 24 21 27 60 7
Conditioning TBI 300cGy TBI 450cGy, TBI 300-450 cGy, CY 60 mg/kg,  CY 20-30 mg/kg, 
CY 40 mg/kg, CY 40 mg/kg,  CY 40 mg/kg,  FLU 125 mg/m2, FLU 125 mg/m2,
FLU 140 mg/m2, FLU 150 mg/m2, FLU 150-180 mg/m2,  ATG, CsA ATG
ATG, CsA ATG, TCD, ATG, 
tacrolimus tacrolimus
Ac GVHD 23% 5,5% 11% 71%
Cr GVHD 5,5% 30% 28%
Follow-up short 5 yrs 3,1 yrs 5 yrs 3 yrs
OS 86% 72% 96% 92% pt<10 yrs age, 100%
53% pt>10 yrs age
CsA: Cyclosporine A.
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advanced MDS or AML in FA patients. A report
of 4 patients treated with a reduced intensity
chemotherapy course (mini-FLAG) showed not
more  than  expected  haematological  toxicity
and no organ toxicity. Three of 4 patients had
a marrow response and could be transplanted
in aplasia, one patient required other chemo  -
therapy to clear blasts pre-HSCT.16 The results
do  not  answer  whether  chemotherapy  given
before HSCT may improve the poor survival. An
alternative  approach  is  to  proceed  to  HSCT
without prior cytoreduction, using TBI 300 cGy,
cyclophosphamide 40 mg, Flu 140 mg, ATG, and
TCD in conditioning regimen.17
Finally,  taking  care  of  a  FA  patient  and
his/her family is a great challenge due to the
delicate balance between treating to cure on
one hand and limiting the damage and side ef-
fects  that  the  treatment  causes  to  a  cross-
linker sensitive patient on the other hand.
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